SCHEMBL4511019

SCHEMBL4511019

O=C(O)CCCCc1cc[nH]c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 1/20 0.58
MAPT P10636 1/20 0.56
RXFP1 Q9HBX9 1/20 0.56
HDAC3 O15379 1/20 0.50
MAPK1 P28482 1/20 0.50
ADRA1A P35348 1/20 0.50
HDAC4 P56524 1/20 0.50
SLC6A3 Q01959 1/20 0.50
HDAC1 Q13547 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC10 Q969S8 1/20 0.50
HDAC11 Q96DB2 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
HDAC9 Q9UKV0 1/20 0.50
HDAC5 Q9UQL6 1/20 0.50
TBXAS1 P24557 8/20 0.47
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1278387 0.94 CAPN1 (0.59) CAPN1MAPTRXFP1HDAC3MAPK1
SCHEMBL608745 0.86 CAPN1 (0.69) CAPN1HDAC3MAPK1ADRA1AHDAC4
SCHEMBL7065645 0.78 MAPT (0.79) MAPTRXFP1HDAC3MAPK1ADRA1A
SCHEMBL20663547 0.77 CAPN1 (0.45) CAPN1SMN1; SMN2
SCHEMBL9671779 0.76 MAPT (0.83) MAPTRXFP1HDAC3MAPK1ADRA1A
SCHEMBL3814880 0.76 MAPT (0.83) MAPTRXFP1HDAC3MAPK1ADRA1A
SCHEMBL7290858 0.75 CAPN1 (0.48) CAPN1MAPTRXFP1
SCHEMBL311759 0.74
SCHEMBL7827144 0.74 MAPT (0.80) MAPTRXFP1HDAC3MAPK1ADRA1A
5-Phenylvaleric Acid SCHEMBL503601 0.74 MAPT (0.96) MAPTRXFP1HDAC3MAPK1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3391876-B1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL SDG INC (US) 2021-03-10 EP disclosed
US-8378058-B2 Conducting polymers and uses thereof AUCKLAND UNISERVICES LIMITED (NZ) 2013-02-19 US disclosed
US-8378058-B2 Conducting polymers and uses thereof AUCKLAND UNISERVICES LIMITED (NZ) 2013-02-19 US disclosed
US-8378058-B2 Conducting polymers and uses thereof AUCKLAND UNISERVICES LIMITED (NZ) 2013-02-19 US disclosed
US-20090215958-A1 CONDUCTING POLYMERS AND USES THEREOF AUCKLAND UNISERVICES LIMITED (NZ) 2009-08-27 US disclosed
US-20090215958-A1 CONDUCTING POLYMERS AND USES THEREOF AUCKLAND UNISERVICES LIMITED (NZ) 2009-08-27 US disclosed
US-20090215958-A1 CONDUCTING POLYMERS AND USES THEREOF AUCKLAND UNISERVICES LIMITED (NZ) 2009-08-27 US disclosed
WO-2007018439-A1 CONDUCTING POLYMERS AND USES THEREOF AUCKLAND UNISERVICES LIMITED (NZ) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215958-A1 CONDUCTING POLYMERS AND USES THEREOF PIN1, PPIA, PARG CAPN1 1686/4885MAPT 821/4885RXFP1 4062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.